Evidence map›Paper›PMID 42212684›Full record

ReviewGut microbes2026

Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.

Jingwen Liu, Pu Zhao, Deming Jiang, Shuyan Li, Chaoqiao Jin, Dingting Xu, Xiaoying Wang, Yan Chen, Bufu Tang, Xudong Qu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingwen LiuDepartment of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Pu ZhaoFourth Clinical College, China Medical University, Shenyang, China.
Deming JiangLaboratory Animal Center, Zhejiang University, Hangzhou, China.
Shuyan LiDepartment of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chaoqiao JinDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Dingting XuDepartment of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaoying WangDepartment of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yan ChenDepartment of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Bufu TangDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.
Xudong QuDepartment of Interventional Radiology, Zhongshan Hospital, Shanghai Institute of Medical Imaging, National Clinical Research Center of Interventional Medicine, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiome functions as a key regulator of tumorigenesis and progression, thereby modulating tumor development and treatment outcomes (including chemoresistance, immunotherapy efficacy, and adverse effects) through its influence on the immune microenvironment and metabolite-mediated signaling pathways. Recent advances in multiomics technologies (metagenomics, metabolomics, and transcriptomics) have generated large-scale, comprehensive, and heterogeneous datasets whose complexity exceeds the capabilities of manual analysis, thus necessitating the implementation of artificial intelligence-based approaches. This review systematically examines the crucial role of the gut microbiome in tumorigenesis, with particular emphasis on colorectal cancer (CRC), specifically addressing its utility as a diagnostic and prognostic biomarker. Furthermore, building upon existing applications of artificial intelligence (AI) in microbiome research and cancer diagnosis and treatment, this review presents an AI-driven precision intervention framework and delineates personalized treatment strategies.

Indexed as

Artificial IntelligenceColorectal NeoplasmsGastrointestinal MicrobiomePrecision MedicineTumor MicroenvironmentAnimalsHumansMultiomicsArtificial intelligencecancercolorectal cancer (CRC)gastrointestinal microbiomeprecision medicineprecision treatment

Identifiers

PMID42212684
PMCPMC13224768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.